TGFB1 and cancer: Inhibition of the TGF‐β pathway remains an active area of interest in cancer research, and TGF‐β‐targeted neutralizing antibodies, vaccines, antisense oligonucleotides, and small‐molecule inhibitors have all been investigated in clinical trials of solid tumors [1, 8].